The 35 references in paper N. Novikova A., A. Volovchenko N., Н. Новикова А., А. Воловченко Н. (2016) “ВАРФАРИН: МЕСТО В СОВРЕМЕННОЙ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ // WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY” / spz:neicon:aterotromboz:y:2016:i:1:p:50-58

1
Camm AJ, Lip GY, De Caterina R, Savelieva I et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal,2012, 33: 2719-2747.
(check this in PDF content)
2
Skanes AC, Healey JS, Cairns JA et al; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol, 2012 Mar-Apr, 28(2): 125-36.
(check this in PDF content)
3
January CT, Wann ST, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society: Executive summary. JACC, 2014: DOI:10.1016/j.jacc.2014.03.021.
(check this in PDF content)
4
Сулимов В.А. и коллектив авторов. Национальные рекомендации по диагностике и лечению фибрилляции предсердий, 2012.
(check this in PDF content)
5
Camm AJ, Lip GY, De Caterina R, Savelieva I et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal, 2012, 33: 2719-2747.
(check this in PDF content)
6
Eikelboom JW, Connolly SJ, Brueckmann M et al. Dabigatran versus warfarin in patients with mechanical heart valves. The New England Journal of Medicine, 2013, 369(13): 1206-1214.
(check this in PDF content)
7
Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for CardioThoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J,2012, 33: 2451-2496.
(check this in PDF content)
8
Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J,2014, 35: 3377-3385.
(check this in PDF content)
9
Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban compared with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE trial. Circulation, 2015, 132: 624-632.
(check this in PDF content)
10
Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes, 2008, 1: 84-91.
(check this in PDF content)
11
Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost,2013, 110: 1189-1198.
(check this in PDF content)
12
Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Sjalander A. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost,2015, 113:
(check this in PDF content)
13
0-1377. 13. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis — Task Force on Anticoagulants in Heart Disease. Thromb Haemost, 2013, 110: 1087-1107.
(check this in PDF content)
14
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet,2014, 383: 955-962.
(check this in PDF content)
15
Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V, Lip GY. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med,2014, 127: 1083-1088.
(check this in PDF content)
16
Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMeTT(2)R(2) score to poorquality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest, 2014, 146: 719-726.
(check this in PDF content)
17
Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest, 2013, 144: 15551563.
(check this in PDF content)
18
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet,2013, 381: 1107-15.
(check this in PDF content)
19
Fiedler KA, Maeng M, Mehilli J et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol, 2015, 65: 1619-1629.
(check this in PDF content)
20
Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation, 2010, 121: 2067-2070.
(check this in PDF content)
21
Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary — Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2010, 31: 13111318.
(check this in PDF content)
22
Faxon DP, Eikelboom JW, Berger PB et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv, 2011, 4: 522-534.
(check this in PDF content)
23
Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific
(check this in PDF content)
24
Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.Br J Clin Pharmacol,2007, 64(3): 292-303.
(check this in PDF content)
25
Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans.Drug metab dispos: biol fate chem.,2009, 37(1): 74-81.
(check this in PDF content)
26
Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.Drug Metab Dispos, 2009, 37(5): 1056-1064.
(check this in PDF content)
27
Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.J Clin Pharmacol, 2012, 52(1 Suppl): 119S-125S.
(check this in PDF content)
28
Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, Friedman J. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.J Clin Pharmacol., 2012, 52(9): 1373-1378.
(check this in PDF content)
29
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 2014, 130(23): 2071-104.
(check this in PDF content)
30
Bauer KA. Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program. 2013, 2013: 464-70.
(check this in PDF content)
31
Dugi K. US FDA Grants Breakthrough Therapy Designation to Pradaxa (dabigatran etexilate) specific Investigational Antidote [Boehringer-Ingelheim press release]. Ingelheim, Germany, 2014.
(check this in PDF content)
32
Portola-Pharmaceuticals. Andexanet alpha: FXa inhibitor antidote: Portola Pharmaceuticals, 2014.
(check this in PDF content)
33
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J, 2013, 34(27): 2094-106.
(check this in PDF content)
34
Albert NM. Use of novel anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Heart Lung, 2014, 43: 48-59.
(check this in PDF content)
35
Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17: 1467-1507.
(check this in PDF content)